EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitSystematische ÜbersichtOpen Access · CC BY-NC 4.0

Clinical efficacy, safety and pharmacokinetics of novel β-lactam/β-lactamase inhibitor combinations: a systematic review

Ana Alarcia-Lacalle iD, Andrés Canut-Blasco, María Ángeles Solinís, Arantxa Isla iD, Alicia Rodríguez-Gascón iD

JAC-Antimicrobial Resistance · 29.04.2025 · 7 (3)

DOI: 10.1093/jacamr/dlaf096 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift JAC-Antimicrobial Resistance, online erschienen am 19.06.2025. Verfasst von Ana Alarcia-Lacalle und 4 weiteren Autor:innen. Beteiligte Einrichtung: Microbiology, Infectious Disease, Antimicrobial Agents, and Gene Therapy, Bioaraba Health Research Institute, Vitoria-Gasteiz, Spain. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 306 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Department of Education of the Basque Government, University of the Basque Country UPV/EHU.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Antimicrobial resistance is a global public health threat that requires urgent solutions. One strategy to decrease resistance of Gram-negative bacteria (GNB) to β-lactam antibiotics (BL) is their combination with β-lactamase inhibitors (BLI).

Objectives

This systematic review analyses the outcomes, safety and pharmacokinetics (PK) of recently approved or under clinical development BLI and BL/BLI combinations.

Methods

The systematic review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. PubMed, Embase, and Cochrane electronic databases were used to search for articles from January 2010 to November 2024. The studies were retrieved and screened on the basis of predefined exclusion and inclusion criteria. A quality assessment of the included studies was conducted following the New Castle-Ottawa Scale.

Results

A total of 191 articles addressing clinical research regarding the efficacy, safety, tolerability, and PK of new BL/BLI combinations with avibactam, durlobactam, enmetazobactam, nacubactam, relebactam, taniborbactam, tazobactam, vaborbactam and zidebactam were included. According to the published literature, clinical research supports the novel BL/BLI combinations for the treatment of complicated urinary tract infections, complicated intra-abdominal infections, and hospital-acquired and ventilator-associated pneumonia (HAP/VAP) caused by GNB. In spite of that, the development of new BLI effective for class B metallo-β-lactamases (MBL) is still challenging, being aztreonam/avibactam the only approved combination active against MBL-producing bacteria.

Conclusions

Although there has been extensive research to develop new BLI and BL/BLI combinations, only a few have reached the market. More evidence of its usefulness in the real world is still needed.

Autor:innen und Institutionen

  • Microbiology, Infectious Disease, Antimicrobial Agents, and Gene Therapy, Bioaraba Health Research Institute, Vitoria-Gasteiz, Spain.
  • Microbiology Service, Osakidetza Basque Health Service, Araba University Hospital, Vitoria-Gasteiz, Spain.
  • Pharmacokinetic, Nanotechnology and Gene Therapy Group (PharmaNanoGene), Faculty of Pharmacy, Centro de Investigación Lascaray Ikergunea, University of the Basque Country UPV/EHU, Vitoria-Gasteiz, Spain.

ORCID-Profile: Ana Alarcia-Lacalle, Arantxa Isla, Alicia Rodríguez-Gascón

Förderung

  • Department of Education of the Basque Government
  • University of the Basque Country UPV/EHU

Zitieren

APA

Alarcia-Lacalle, A., Canut-Blasco, A., Solinís, M. Á., Isla, A., & Rodríguez-Gascón, A. (2025). Clinical efficacy, safety and pharmacokinetics of novel β-lactam/β-lactamase inhibitor combinations: a systematic review. JAC-Antimicrobial Resistance, 7(3). https://doi.org/10.1093/jacamr/dlaf096

Vancouver

Alarcia-Lacalle A, Canut-Blasco A, Solinís MÁ, Isla A, Rodríguez-Gascón A. Clinical efficacy, safety and pharmacokinetics of novel β-lactam/β-lactamase inhibitor combinations: a systematic review. JAC-Antimicrobial Resistance. 2025;7(3). doi:10.1093/jacamr/dlaf096

BibTeX
@article{AlarciaLacalle2025,
  author = {Alarcia-Lacalle, Ana and Canut-Blasco, Andrés and Solinís, María Ángeles and Isla, Arantxa and Rodríguez-Gascón, Alicia},
  title = {Clinical efficacy, safety and pharmacokinetics of novel β-lactam/β-lactamase inhibitor combinations: a systematic review},
  journal = {JAC-Antimicrobial Resistance},
  year = {2025},
  volume = {7},
  number = {3},
  doi = {10.1093/jacamr/dlaf096}
}
Kostenlos starten →